ProQR Therapeutics NV expected to post a loss of 21 cents a share - Earnings Preview

ProQR Therapeutics NV

31/10/2022 15:01

* ProQR Therapeutics NV  PRQR.OQ   PRQR.O  is expected
to show a
fall in quarterly revenue when it reports  results on November 2
(estimated). 
    * The Leiden Zuid-holland-based  company is expected to
report  a
27.5% decrease in revenue to €838.99 thousand from €1.16 million
a year ago, according to the mean estimate from 6 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for ProQR Therapeutics
NV is
for a loss of 21 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for ProQR
Therapeutics NV is $1.5​, above​ its last closing price
of $0.93. ​​​

Previous quarterly performance (using preferred earnings measure
in euros). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.22       -0.22      -0.21     Beat    2.7
 Mar. 31 2022  -0.24       -0.24      -0.20     Beat    15.1
 Dec. 31 2021  -0.18       -0.19      -0.26     Missed  -40​
 Sep. 30 2021  -0.20       -0.21      -0.22     Missed  -7.3
 ​​Jun.        -0.22       -0.24      -0.24     Met     -1.2
 30 2021                                                
 Mar. 31 2021  -0.25       -0.25      -0.25     Met     -0.1​
 Dec. 31 2020  -0.25       -0.25      -0.26     Missed  -3.6
 Sep. 30 2020  -0.30       -0.30      -0.26     Beat    13.5
 This summary was machine generated October 31 at 15:01 GMT.  All
figures in euros  unless otherwise stated